EuBiologics Co Ltd
KOSDAQ:206650
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EuBiologics Co Ltd
Accounts Payable
EuBiologics Co Ltd
Accounts Payable Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Accounts Payable | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
E
|
EuBiologics Co Ltd
KOSDAQ:206650
|
Accounts Payable
₩5.5B
|
CAGR 3-Years
86%
|
CAGR 5-Years
94%
|
CAGR 10-Years
N/A
|
|
|
Celltrion Inc
KRX:068270
|
Accounts Payable
₩124.6B
|
CAGR 3-Years
35%
|
CAGR 5-Years
30%
|
CAGR 10-Years
38%
|
|
|
SK Bioscience Co Ltd
KRX:302440
|
Accounts Payable
₩35.3B
|
CAGR 3-Years
47%
|
CAGR 5-Years
15%
|
CAGR 10-Years
N/A
|
|
|
V
|
Voronoi Inc
KOSDAQ:310210
|
Accounts Payable
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Alteogen Inc
KOSDAQ:196170
|
Accounts Payable
₩11.2B
|
CAGR 3-Years
312%
|
CAGR 5-Years
91%
|
CAGR 10-Years
N/A
|
|
|
A
|
ABL Bio Inc
KOSDAQ:298380
|
Accounts Payable
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
EuBiologics Co Ltd
Glance View
EuBiologics Co., Ltd. engages in the research, development, and manufacture of biopharmaceutical products. The company is headquartered in Seoul, Seoul and currently employs 323 full-time employees. The company went IPO on 2017-01-24. The firm operates its business through two segments. The Vaccine segment manufactures and sells oral cholera vaccines. The Contract Research and Manufacturing Organization (CRMO) segment contracts, researches and manufactures biopharmaceuticals.
See Also
What is EuBiologics Co Ltd's Accounts Payable?
Accounts Payable
5.5B
KRW
Based on the financial report for Dec 31, 2025, EuBiologics Co Ltd's Accounts Payable amounts to 5.5B KRW.
What is EuBiologics Co Ltd's Accounts Payable growth rate?
Accounts Payable CAGR 5Y
94%
Over the last year, the Accounts Payable growth was -52%. The average annual Accounts Payable growth rates for EuBiologics Co Ltd have been 86% over the past three years , 94% over the past five years .
